Bausch Health says it has acquired the US rights to Eton Pharmaceuticals' EM-100 investigational eye drop for the treatment of itchy eyes associated with allergies. EM-100 has been submitted to the FDA for review as an over-the-counter (OTC) preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis.

"EM-100 is a new, differentiated eye drop that will complement Bausch + Lomb's broad range of integrated eye health products," said Bausch Health chairman Joseph Papa. "If approved, EM-100 will be the first preservative-free allergy eye drop available in the United States."

Eton Pharmaceuticals previously reported positive top-line results from a Phase 3 trial in which EM-100 demonstrated statistically significant superiority to a placebo and no adverse events, and demonstrated non-inferiority to a comparator product in the treatment of ocular itching.

"We believe that partnering with Bausch + Lomb, a global leader in consumer ophthalmology, will allow us to maximize EM-100's commercial potential and provide broad accessibility for patients," said Eton Pharmaceuticals CEO, Sean Brynjelsen.